Sweet and Sour - oxidative and carbonyl stress in neurological disorders

CNS and Neurological Disorders - Drug Targets

Volumn 10, Issue 1, 2011, Pages 82-107

  Harris, Robert A ^a   Amor, Sandra ^b,c  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Advanced glycation endproducts; Advanced oxidation protein products; Multiple sclerosis; Neurodegeneration; Oxidative stress

Indexed keywords

ALAGEBRIUM; ALPHA TOCOPHEROL; AMINOGUANIDINE; AMYLOID A PROTEIN; AMYLOID BETA PROTEIN; ATORVASTATIN; CARBOHYDRATE; CARBONYL DERIVATIVE; CARNOSINE; EBSELEN; FENOFIBRATE; HIGH MOBILITY GROUP B1 PROTEIN; IRBESARTAN; LIPID; METFORMIN; NIFEDIPINE; OLMESARTAN; PENTOXIFYLLINE; PIGMENT EPITHELIUM DERIVED FACTOR; PRION PROTEIN; PROANTHOCYANIDIN; PROTEIN; PROTEIN S 100; PYRIDOXAMINE; TANSHINONE IIA; TELMISARTAN; TEMOCAPRILAT; THIOCTIC ACID; UNINDEXED DRUG; VALSARTAN; ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCOSYLATION END PRODUCT RECEPTOR; ADVANCED GLYCOSYLATION END-PRODUCT RECEPTOR; ANTIOXIDANT; IMMUNOGLOBULIN RECEPTOR; REACTIVE OXYGEN METABOLITE;

AGING; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; BIPOLAR DISORDER; BRAIN INJURY; COGNITION; CREUTZFELDT JAKOB DISEASE; DIFFUSE LEWY BODY DISEASE; DOWN SYNDROME; FRIEDREICH ATAXIA; GLIOBLASTOMA; GLYCATION; HEADACHE; HISTOPATHOLOGY; HOMEOSTASIS; HUMAN; LIPID PEROXIDATION; MENINGITIS; MULTIPLE SCLEROSIS; NERVE FIBER GROWTH; NERVE REGENERATION; NEUROLOGIC DISEASE; NEUROTOXICITY; NIEMANN PICK DISEASE; NONHUMAN; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PARKINSON DISEASE; PROTEOMICS; PYRIDOXINE DEFICIENCY; RADIATION INJURY; REVIEW; SCHIZOPHRENIA; SPINAL CORD INJURY; STROKE; TRAUMATIC BRAIN INJURY; DEGENERATIVE DISEASE; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY;

ANTIOXIDANTS; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; LIPID PEROXIDATION; MOLECULAR TARGETED THERAPY; NERVOUS SYSTEM DISEASES; NEURODEGENERATIVE DISEASES; OXIDATION-REDUCTION; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; RECEPTORS, IMMUNOLOGIC;

EID: 79960995847     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/187152711794488656     Document Type: Review

References (339)

1. Dalle-Donne, I.; Giustarini, D.; Colombo, R.; Rossi, R.; Milzani, A. Protein carbonylation in human diseases. Trends Mol. Med., 2003, 9,169-179.
2. Pacher, P.; Beckman, J.S.; Liaudet, L. Nitric oxide and peroxynitrite in health and disease. Physiol. Rev., 2007, 87, 315-424.
3. Sayre, L.M.; Perry, G.; Smith, M.A. Oxidative stress and neurotoxicity. Chem. Res. Toxicol., 2008, 21,172-188.
4. Kalousová, M.; Zima, T.; Tesar, V.; Dusilová-Sulková, S.; Skrha, J. Advanced glycoxidation end products in chronic diseases-clinical chemistry and genetic background. Mutat. Res., 2005, 579, 37-46.
5. Costello, C.E.; Contado-Miller, J.M.; Cipollo, J.F.A. Glycomics platform for the analysis of permethylated oligosaccharide alditols. J. Am. Soc. Mass Spectrom., 2007, 18,1799-1812.
6. Priego-Capote, F.; Sanchez, J.C. Strategies for proteomic analysis of non-enzymatically glycated proteins. Mass Spectrom. Rev., 2009, 28,135146.
7. Ulrich, P.; Cerami, A. Protein glycation, diabetes, and aging. Recent Prog. Horm. Res., 2001, 56, 1-21.
8. Horiuchi, S.; Higashi, T.; Ikeda, K.; Saishoji, T.; Jinnouchi, Y.; Sano, H.; Shibayama, R.; Sakamoto, T.; Araki, N. Advanced glycation end products and their recognition by macrophage and macrophage-derived cells. Diabetes, 1996, 45, 73-76.
9. Schaur, R.J. Basic aspects of the biochemical reactivity of 4- hydroxynonenal Mol. Aspects Med., 2003, 24,149-159.
10. Aldini, G.; Dalle-Donne, I.; Facino, R.M.; Milzani, A.; Carini, M.; Intervention strategies to inhibit protein carbonylation by lipoxidation-derived reactive carbonyls. Med. Res. Rev., 2007, 27, 817-868.
11. Steinbrecher, U.P. Receptors for oxidized low density lipoprotein. Biochim. Biophys. Acta, 1999, 1436, 279-298.
12. Zarkovic, K. 4-hydroxynonenal and neurodegenerative diseases. Mol. Aspects Med., 2003, 24, 293-303.
13. Bruce-Keller, A.J.; Li, Y.J.; Lovell, M.A.; Kraemer, P.J.; Gary, D.S.; Brown, R.R.; Markesbery, W.R.; Mattson, M.P. 4- Hydroxynonenal, a product of lipid peroxidation, damages cholinergic neurons and impairs visuospatial memory in rats. J. Neuropathol. Exp. Neurol., 1998, 57, 257-267.
14. Keller, J.N.; Steiner, M.R.; Holtsberg, F.W.; Mattson, M.P.; Steiner, S.M. Lysophosphatidic acid-induced proliferation-related signals in astrocytes. J. Neurochem., 1997, 69, 1073-1084.
15. Kruman, I.; Bruce-Keller, A.J.; Bredesen, D.; Waeg, G.; Mattson, M.P. Evidence that 4-hydroxynonenal mediates oxidative stress- induced neuronal apoptosis. J. Neurosci., 1997, 17, 5089-5100.
16. Lovell, M.A.; Xie, C.; Markesbery, W.R. Acrolein is increased in Alzheimer's disease brain and is toxic to primary hippocampal cultures. Neurobiol. Aging, 2001, 22, 187-194.
17. Witko-Sarsat, V.; Friedlander, M.; Capeillère-Blandin, C.; Nguyen- Khoa, T.; Nguyen, A.T.; Zingraff, J.; Jungers, P.; Descamps- Latscha, B. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int., 1996, 49, 1304-1313.
18. Capeillère-Blandin, C.; Gausson, V.; Descamps-Latscha, B.; Witko-Sarsat, V. Biochemical and spectrophotometric significance of advanced oxidized protein products. Biochim. Biophys. Acta, 2004, 1689, 91-102.
19. Guo, Z.Y.; Qiao, Z.S.; Feng, Y.M. The in vitro oxidative folding of the insulin superfamily. Antioxid. Redox Signal., 2008, 10, 127-139.
20. Rockwell, P.; Yuan, H.; Magnusson, R.; Figueiredo-Pereira, M.E. Proteasome inhibition in neuronal cells induces a proinflammatory response manifested by upregulation of cyclooxygenase-2, its accumulation as ubiquitin conjugates, and production of the prostaglandin PGE(2). Arch. Biochem. Biophys., 2000, 374, 325-333.
21. Shringarpure, R.; Grune, T.; Sitte, N.; Davies, K.J. 4- Hydroxynonenal-modified amyloid-beta peptide inhibits the proteasome: possible importance in Alzheimer's disease. Cell Mol. Life Sci., 2000, 57, 1802-1809.
22. Thornalley, P.J.; Battah, S.; Ahmed, N.; Karachalias, N.; Agalou, S.; Babaei-Jadidi, R.; Dawnay, A. Quantitative screening of advanced glycation endproducts in cellular and extracellular proteins by tandem mass spectrometry. Biochem. J., 2003, 375, 581-592.
23. Pilobello, K.T.; Mahal, L.K. Deciphering the glycocode: the complexity and analytical challenge of glycomics. Curr. Opin. Chem. Biol., 2007, 11, 300-305.
24. Timmer, M.S.; Stocker, B.L,; Seeberger, P.H. Probing glycomics. Curr. Opin. Chem. Biol., 2007, 11, 59-65.
25. Nicholl, I.D.; Bucala, R. Advanced glycation endproducts and cigarette smoking. Cell. Mol. Biol., 1998, 44, 1025-1033.
26. Esterbauer, H.; Schaur, R.J.; Zollner, H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic. Biol. Med., 1991, 11, 81-128.
27. Pinel-Marie, M.L.; Sparfel, L.; Desmots, S.; Fardel, O. Aryl hydrocarbon receptor-dependent induction of the NADPH oxidase subunit NCF1/p47 phox expression leading to priming of human macrophage oxidative burst. Free Radic. Biol. Med., 2009, 47, 825-834.
28. Neeper, M.; Schmidt, A.M.; Brett, J.; Yan, S.D.; Wang, F.; Pan, Y.C.; Elliston, K.; Stern, D.; Shaw, A. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J. Biol. Chem., 1992, 267, 14998-5004.
29. Huttunen, H.J.; Kuja-Panula, J.; Sorci, G.; Agneletti, A.L.; Donato, R.; Rauvala, H. Coregulation of neurite outgrowth and cell survival by amphoterin and S100 proteins through receptor for advanced glycation end products (RAGE) activation. J. Biol. Chem., 2000, 275, 40096-40105.
30. Dattilo, B.M.; Fritz, G.; Leclerc, E.; Kooi, C.W.; Heizmann, C.W.; Chazin, W.J. The extracellular region of the receptor for advanced glycation end products is composed of two independent structural units. Biochemistry, 2007, 46, 6957-6970.
31. Srikrishna, G.; Huttunen, H.J.; Johansson, L.; Weigle, B.; Yamaguchi, Y.; Rauvala, H.; Freeze, H.H. N -Glycans on the receptor for advanced glycation end products influence amphoterin binding and neurite outgrowth. J. Neurochem., 2002, 80, 998-1008.
32. Ishihara, K.; Tsutsumi, K.; Kawane, S.; Nakajima, M.; Kasaoka, T. The receptor for advanced glycation end-products (RAGE) directly binds to ERK by a D-domain-like docking site. FEBS Lett., 2003, 550, 107-113.
33. Matsumoto, S.; Yoshida, T.; Murata, H.; Harada, S.; Fujita, N.; Nakamura, S.; Yamamoto, Y.; Watanabe, T.; Yonekura, H.; Yamamoto, H.; Ohkubo, T.; Kobayashi, Y. Solution structure of the variable-type domain of the receptor for advanced glycation end products: new insight into AGE-RAGE interaction. Biochemistry, 2008, 47, 12299-12311.
34. Nagai, R.; Matsumoto, K.; Ling, X.; Suzuki, H.; Araki, T.; Horiuchi, S. Glycolaldehyde, a reactive intermediate for advanced glycation end products, plays an important role in the generation of an active ligand for the macrophage scavenger receptor. Diabetes, 2000, 49, 1714-1723.
35. Ostendorp, T.; Leclerc, E.; Galichet, A.; Koch, M.; Demling, N.; Weigle, B.; Heizmann, C.W.; Kroneck, P.M.; Fritz, G. Structural and functional insights into RAGE activation by multimeric S100B. EMBO J., 2007, 26, 3868-3878.
36. Xie, J.; Reverdatto, S.; Frolov, A.; Hoffmann, R.; Burz, D.S.; Shekhtman, A. Structural basis for pattern recognition by the receptor for advanced glycation end products (RAGE). J. Biol. Chem., 2008, 283, 27255-27269.
37. Bierhaus, A.; Schiekofer, S.; Schwaninger, M.; Andrassy, M.; Humpert, P.M.; Chen, J. Hong, M.; Luther, T.; Henle, T.; Klöting, I.; Morcos, M.; Hofmann, M.; Tritschler, H.; Weigle, B. Kasper, M.; Smith, M.; Perry, G.; Schmidt, A.M.; Stern, D.M;. Häring, H.U.; Schleicher, E.; Nawroth, P.P. Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB. Diabetes, 2001, 50, 2792-2808.
38. Bopp, C.; Bierhaus, A.; Hofer, S.; Bouchon, A.; Nawroth, P.P.; Martin, E.; Weigand, M.A. Bench-to-bedside review: The inflammation-perpetuating pattern-recognition receptor RAGE as a therapeutic target in sepsis. Crit. Care, 2008, 12, 201-208.
39. Raucci, A.; Cugusi, S.; Antonelli, A.; Barabino, S.M.; Monti, L.; Bierhaus, A.; Reiss, K.; Saftig, P.; Bianchi M.E. A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10). FASEB J., 2008, 22, 3716-3727.
40. Ding, Q.; Keller J.N. Splice variants of the receptor for advanced glycosylation end products (RAGE) in human brain. Neurosci. Lett., 2005, 373, 67-72.
41. Park, IH, Yeon, SI, Youn, JH, Choi, JE, Sasaki, N, Choi, IH, Shin JS. Expression of a novel secreted splice variant of the receptor for advanced glycation end products (RAGE) in human brain astrocytes and peripheral blood mononuclear cells. Mol. Immunol., 2004, 40, 1203-1211.
42. Kalea, A.Z.; Reiniger, N.; Yang, H.; Arriero, M.; Schmidt, A.M.; Hudson, B.I. Alternative splicing of the murine receptor for advanced glycation end-products (RAGE) gene. FASEB J., 2009, 23(6), 1766-1774.
43. Ding, Q.; Keller, J.N. Evaluation of rage isoforms, ligands, and signaling in the brain. Biochim Biophys Acta, 2005, 1746(1), 18-27.
44. Cheng, C.; Tsuneyama, K. Kominami, R.; Shinohara, H.; Sakurai, S.; Yonekura, H.; Watanabe, T.; Takano, Y.; Yamamoto, H.; Yamamoto, Y. Expression profiling of endogenous secretory receptor for advanced glycation end products in human organs. Mod. Pathol., 2005, 18, 1385-1396.
45. Brett, J.; Schmidt, A.M.; Yan, S.D.; Zou, Y.S.; Weidman, E.; Pinsky, D.; Nowygrod, R.; Neeper, M.; Przysiecki, C.; Shaw, A.; Migheli A.; Stern, D. Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. Am. J. Pathol., 1993, 143, 1699-1712.
46. Yan, S.D.; Chen, X.; Fu, J.; Chen, M.; Zhu, H.; Roher, A.; Slattery, T.; Zhao, L.; Nagashima, M.; Morser, J.; Migheli, A.; Nawroth, P.; Stern, D.; Schmidt, A.M. RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature, 1996, 382, 685-691.
47. Deane, R.; Du Yan, S.; Submamaryan, R.K.; LaRue, B.; Jovanovic, S.; Hogg, E.; Welch, D.; Manness, L.; Lin, C.; Yu, J.; Zhu, H.; Ghiso, J.; Frangione, B.; Stern, A.; Schmidt, A.M.; Armstrong, D.L.; Arnold, B.; Liliensiek, B.; Nawroth, P.; Hofman, F.; Kindy, M.; Stern, D.; Zlokovic, B. RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat. Med., 2003, 9, 907-913.
48. Arancio, O.; Zhang, H.P.; Chen, X.; Lin, C.; Trinchese, F.; Puzzo, D.; Liu, S.; Hegde, A.; Yan, S.F.; Stern, A.; Luddy, J.S.; Lue, L.F.; Walker, D.G.; Roher, A.; Buttini, M.; Mucke, L.; Li W.; Schmidt, A.M.; Kindy, M.; Hyslop, P.A.; Stern, D.M.; Du Yan, S.S. RAGE potentiates Abeta-induced perturbation of neuronal function in transgenic mice. EMBO J., 2004, 23, 4096-4105.
49. Qin, J.; Goswami, R.; Dawson, S.; Dawson, G. Expression of the receptor for advanced glycation end products in oligodendrocytes in response to oxidative stress. J. Neurosci. Res., 2008, 86, 2414-2422.
50. Vincent, A.M.; Perrone, L.; Sullivan, K.A.; Backus, C.; Sastry, A.M.; Lastoskie, C.; Feldman, E.L. Receptor for advanced glycation end products activation injures primary sensory neurons via oxidative stress. Endocrinology, 2007, 148, 548-558.
51. Hofmann, M.A.; Drury, S.; Fu, C.; Qu, W.; Taguchi, A.; Lu, Y.; Avila, C.; Kambham, N.; Bierhaus, A.; Nawroth, P.; Neurath, M.F.; Slattery, T.; Beach, D.; McClary, J.; Nagashima, M.; Morser, J.; Stern, D.; Schmidt, A.M.; RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell, 1999, 97, 889-901.
52. Rong, L.L.; Yan, S.F.; Wendt, T.; Hans, D.; Pachydaki, S.; Bucciarelli, L.G.; Adebayo, A.; Qu, W.; Lu, Y.; Kostov, K.; Lalla, E.; Yan, S.D.; Gooch, C.; Szabolcs, M.; Trojaborg, W.; Hays, A.P.; Schmidt, A.M. RAGE modulates peripheral nerve regeneration via recruitment of both inflammatory and axonal outgrowth pathways. FASEB J., 2004, 18, 1818-1825.
53. Pichiule, P.; Chavez, J.C.; Schmidt, A.M.; Vannucci, S.J. Hypoxia- inducible factor-1 mediates neuronal expression of the receptor for advanced glycation end products following hypoxia/ischemia. J. Biol. Chem., 2007, 282, 36330-36340.
54. Hori, O.; Brett, J.; Slattery, T.; Cao, R.; Zhang, J.; Chen, J.X.; Nagashima, M.; Lundh, E.R.; Vijay, S.; Nitecki, D.; Morser, J.; Stern, D.; Schmidt A.M.The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system. J. Biol. Chem., 1995, 270, 25752-25761.
55. Passalacqua, M.; Patrone, M.; Picotti, G.B.; Del Rio, M.; Sparatore, B.; Melloni, E.; Pontremoli, S. Stimulated astrocytes release high- mobility group 1 protein, an inducer of LAN-5 neuroblastoma cell differentiation. Neuroscience, 1998, 82, 1021-1028.
56. Wang, L.; Li, S.; Jungalwala, F.B.; Receptor for advanced glycation end products (RAGE) mediates neuronal differentiation and neurite outgrowth. J. Neurosci. Res., 2008, 86, 1254-1266.
57. Previtali, S.C.; Nodari, A.; Taveggia, C.; Pardini, C, Dina, G, Villa, A.; Wrabetz, L.; Quattrini, A.; Feltri, M.L. Expression of laminin receptors in schwann cell differentiation: evidence for distinct roles. Neuroscience, 2003, 23, 5520-5530.
58. Dobrowsky, RT.; Rouen, S.; Yu, C.; Altered neurotrophism in diabetic neuropathy: spelunking the caves of peripheral nerve. J. Pharmacol. Exp. Ther., 2005, 313, 485-491.
59. Perrone, L.; Peluso, G.; Melone, M.A. RAGE recycles at the plasma membrane in S100B secretory vesicles and promotes Schwann cells morphological changes. J. Cell. Physiol., 2008, 217, 60-71.
60. Bierhaus, A.; Humpert, P.M.; Morcos, M.; Wendt, T.; Chavakis, T.; Arnold, B.; Stern, D.M.; Nawroth, P.P. Understanding RAGE, the receptor for advanced glycation end products. J. Mol. Med., 2005, 83, 876-886.
61. Kalea, A.Z.; Schmidt, A.M.; Hudson, B.I. RAGE: a novel biological and genetic marker for vascular disease. Clin. Sci., 2009, 116, 621-637.
62. Bierhaus, A.; Nawroth, P.P. Multiple levels of regulation determine the role of the receptor for AGE (RAGE) as common soil in inflammation, immune responses and diabetes mellitus and its complications. Diabetologia, 2009, 52, 2251-2263.
63. Ramasamy, R.; Vannucci, S.J.; Yan, S.S.; Herold, K.; Yan, S.F.; Schmidt, A.M. Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation. Glycobiology, 2005, 15, 16-28.
64. Ramasamy, R.; Yan, S.F.; Schmidt, A.M. RAGE: therapeutic target and biomarker of the inflammatory response-the evidence mounts. J. Leukoc. Biol., 2009, 86, 505-512.
65. Herold, K.; Moser, B.; Chen, Y.; Zeng, S.; Yan, S.F.; Ramasamy, R.; Emond, J.; Clynes, R.; Schmidt, A.M. Receptor for advanced glycation end products (RAGE) in a dash to the rescue: inflammatory signals gone awry in the primal response to stress. J. Leukoc. Biol., 2007, 82, 204-212.
66. Yan, S.F.; Ramasamy, R.; Schmidt, A.M. Receptor for AGE (RAGE) and its ligands-cast into leading roles in diabetes and the inflammatory response. J. Mol. Med., 2009, 87, 235-247.
67. Schmidt, A.M.; Yan, S.D.; Yan, S.F.; Stern, D.M. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J. Clin. Invest., 2001, 108, 949-955.
68. Sparvero, L.J.; Asafu-Adjei, D.; Kang, R.; Tang, D.; Amin, N.; Im, J.; Rutledge, R.; Lin, B.; Amoscato, A.A.; Zeh, H, Lotze, M.T. RAGE (Receptor for Advanced Glycation Endproducts), RAGE ligands, and their role in cancer and inflammation. J. Transl. Med., 2009, 17, 17-38.
69. Vlassara, H.; Li, Y.M.; Imani, F.; Wojciechowicz, D.; Yang, Z.; Liu, F.; Cerami, A. Identification of galectin-3 as a high-affinity binding protein for advanced glycation end products (AGE): a new member of the AGE-receptor complex. Mol. Med., 1995, 1, 634-646.
70. Iacobini, C.; Menini, S.; Ricci, C.; Scipioni, A.; Sansoni, V.; Mazzitelli, G.; Cordone, S.; Pesce, C.; Pugliese, F.; Pricci, F.; Pugliese, G. Advanced lipoxidation end-products mediate lipidinduced glomerular injury: role of receptor-mediated mechanisms. Pathol., 2009, 218, 360-369.
71. Andersson, U.; Erlandsson-Harris, H.; Yang, H.; Tracey, K.J. HMGB1 as a DNA-binding cytokine. J. Leukoc. Biol., 2002, 72, 1084-1091.
72. Rauvala, H.; Pihlaskari, R. Isolation and some characteristics of an adhesive factor of brain that enhances neurite outgrowth in central neurons. J. Biol. Chem., 1987, 262, 16625-16635.
73. Guazzi, S.; Strangio, A.; Franzi, A.T.; Bianchi, M.E. MGB1, an architectural chromatin protein and extracellular signalling factor, has a spatially and temporally restricted expression pattern in mouse brain. Gene. Expr. Patterns, 2003, 3, 29-33.
74. Pedrazzi, M.; Raiteri, L.; Bonanno, G.; Patrone, M.; Ledda, S.; Passalacqua, M.; Milanese, M.; Melloni, E.; Raiteri, M.; Pontremoli, S.; Sparatore, B. Timulation of excitatory amino acid release from adult mouse brain glia subcellular particles by high mobility group box 1 protein. Neurochemistry, 2006, 99, 827-838.
75. Faraco, G.; Fossati, S.; Bianchi, M.E.; Patrone, M.; Pedrazzi, M.; Sparatore, B.; Moroni, F.; Chiarugi, A. High mobility group box 1 protein is released by neural cells upon different stresses and worsens ischemic neurodegeneration in vitro and in vivo. J. Neurochem., 2007, 103, 590-603.
76. Kim, J.B.; Sig Choi, J.; Yu, Y.M.; Nam, K.; Piao, C.S.; Kim, S.W.; Lee, M.H.; Han, P.L.; Park, J.S.; Lee, J.K. HMGB1, a novel cytokine-like mediator linking acute neuronal death and delayed neuroinflammation in the postischemic brain. Neuroscience, 2006, 26, 6413-6421.
77. Goldstein, R.S.; Gallowitsch-Puerta, M.; Yang, L.; Rosas-Ballina, M.; Huston, J.M.; Czura, C.J.; Lee, D.C.; Ward, M.F.; Bruchfeld, A.N.; Wang, H.; Lesser, M.L.; Church, A.L.; Litroff, A.H.; Sama, A.E.; Tracey, K.J. Elevated high-mobility group box 1 levels in patients with cerebral and myocardial ischemia. Shock, 2006, 25, 571-574.
78. Agnello, D.; Wang, H.; Yang, H.; Tracey, K.J.; Ghezzi, P. MGB-1, a DNA-binding protein with cytokine activity, induces brain TNF and IL-6 production, and mediates anorexia and taste aversion. Cytokine, 2002, 18, 231-236.
79. O'Connor, K.A.; Hansen, M.K.; Rachal Pugh, C.; Deak, M.M.; Biedenkapp, J.C.; Milligan, E.D.; Johnson, J.D.; Wang, H.; Maier, S.F.; Tracey, K.J.; Watkins, L.R. Further characterization of high mobility group box 1 (HMGB1) as a proinflammatory cytokine: central nervous system effects. Cytokine, 2003, 24, 254-265.
80. Andersson, A.; Covacu, R.; Sunnemark, D.; Danilov, A.I.; Dal Bianco, A.; Khademi, M.; Wallström, E.; Lobell, A.; Brundin, L.; Lassmann, H.; Harris, R.A. Pivotal advance: HMGB1 expression in active lesions of human and experimental multiple sclerosis. J. Leukoc. Biol., 2008, 84, 1248-1255.
81. Kawabata, H.; Setoguchi, T.; Yone, K.; Souda, M.; Yoshida, H.; Kawahara, K.I.; Maruyama, I.; Komiya, S. High mobility group box 1 is upregulated after spinal cord injury and is associated with neuronal cell apoptosis. Spine, 2010, 15, 1109-1115
82. Chavakis, T.; Bierhaus, A.; Al-Fakhri, N.; Schneider, D.; Witte, S.; Linn, T.; Nagashima M.; Morser, J.; Arnold, B.; Preissner, K.T.; Nawroth, P.P. The pattern recognition receptor (RAGE) is a counterreceptor for leukocyte integrins: a novel pathway for inflammatory cell recruitment. J. Exp. Med., 2003, 198, 1507-1515.
83. Orlova, V.V.; Choi, E.Y.; Xie, C.; Chavakis, E.; Bierhaus, A.; Ihanus, E.; Ballantyne, C.M.; Gahmberg, C.G.; Bianchi, M.E.; Nawroth, P.P.; Chavakis, T. A novel pathway of HMGB1-mediated inflammatory cell recruitment that requires Mac-1-integrin. EMBO J., 2007, 26, 1129-1139.
84. Pullerits, R.; d'Elia, H.F.; Tarkowski, A.; Carlsten, H. The decrease of soluble RAGE levels in rheumatoid arthritis patients following hormone replacement therapy is associated with increased bone mineral density and diminished bone/cartilage turnover: a randomized controlled trial. Rheumatology, 2009, 48, 785-790.
85. Xie, J.; Burz, D.S.; He, W.; Bronstein, I.B.; Lednev, I.; Shekhtman, A. Hexameric calgranulin C (S100A12) binds to the receptor for advanced glycated end products (RAGE) using symmetric hydrophobic target-binding patches. J. Biol. Chem., 2007, 282, 4218-4231.
86. Leclerc, E.; Fritz, G.; Weibel, M.; Heizmann, C.W.; Galichet, A. S100B and S100A6 differentially modulate cell survival by interacting with distinct RAGE (receptor for advanced glycation end products) immunoglobulin domains. J. Biol. Chem., 2007, 282, 31317-31331.
87. Steiner, J.; Walter, M.; Wunderlich, M.T.; Bernstein, H.G.; Panteli, B.; Brauner, M.; Jacobs, R.; Gos, T.; Rothermundt, M.; Bogerts, B. A new pathophysiological aspect of S100B in schizophrenia: potential regulation of S100B by its scavenger soluble RAGE. Biol. Psychiatry, 2009, 65, 1107-1110.
88. Yan, L.J.; Levine, R.L.; Sohal, R.S. Oxidative damage during aging targets mitochondrial aconitase. Proc. Natl. Acad. Sci., 1997, 94, 11168-11172.
89. Mackic, J.B.; Stins, M.; McComb, J.G.; Calero, M.; Ghiso, J.; Kim, K.S.; Yan, S.D.; Stern, D.; Schmidt, A.M.; Frangione, B.; Zlokovic, B.V. Human blood-brain barrier receptors for Alzheimer's amyloid-beta 1- 40. Asymmetrical binding, endocytosis, and transcytosis at the apical side of brain microvascular endothelial cell monolayer. J. Clin. Invest., 1998, 102, 734-743.
90. Yan, S.D.; Zhu, H.; Zhu, A.; Golabek, A.; Du, H.; Roher, A.; Yu, J.; Soto, C.; Schmidt, A.M.; Stern, D.; Kindy, M. Receptor- dependent cell stress and amyloid accumulation in systemic amyloidosis. Nat. Med., 2000, 6, 643-651.
91. Sasaki, N.; Takeuchi, M.; Chowei, H.; Kikuchi, S.; Hayashi, Y.; Nakano, N.; Ikeda, H.; Yamagishi, S.; Kitamoto, T.; Saito, T.; Makita, Z. Advanced glycation end products (AGE) and their receptor (RAGE) in the brain of patients with Creutzfeldt-Jakob disease with prion plaques. Neurosci. Lett., 2002, 326, 117-120.
92. Crocker, P.R.; Redelinghuys, P. Siglecs as positive and negative regulators of the immune system. Biochem. Soc. Trans., 2008, 36, 1467-1471.
93. Kanazawa, N. Dendritic cell immunoreceptors: C-type lectin receptors for pattern-recognition and signaling on antigen- presenting cells. J. Dermatol. Sci., 2007, 45, 77-86.
94. Rauvala, H.; Rouhiainen, A. Physiological and pathophysiological outcomes of the interactions of HMGB1 with cell surface receptors. Biochim. Biophys. Acta, 2010, 1799, 164-170.
95. Sugaya, K.; Fukagawa, T.; Matsumoto, K.; Mita, K.; Takahashi, E.; Ando, A.; Inoko, H.; Ikemura, T. Three genes in the human MHC class III region near the junction with the class II: gene for receptor of advanced glycosylation end products, PBX2 homeobox gene and a notch homolog, human counterpart of mouse mammary tumor gene int-3. Genomics, 1994, 23, 408-419.
96. Rhodes, D.A.; Trowsdale, J. Genetics and molecular genetics of the MHC. Rev. Immunogenet., 1999, 1, 21-31.
97. Hudson, B.I.; Stickland, M.H.; Grant, P.J.; Futers, T.S. Characterization of allelic and nucleotide variation between the RAGE gene on chromosome 6 and a homologous pseudogene sequence to its 5' regulatory region on chromosome 3: implications for polymorphic studies in diabetes. Diabetes, 2001, 50, 2646-2651.
98. Hofmann, M.A.; Drury, S.; Hudson, B.I.; Gleason, M.R.; Qu, W.; Lu, Y.; Lalla, E.; Chitnis, S.; Monteiro, J.; Stickland, M.H.; Bucciarelli, L.G.; Moser, B.; Moxley, G.; Itescu, S.; Grant, P.J.; Gregersen, P.K.; Stern, D.M.; Schmidt, A.M. RAGE and arthritis: the G82S polymorphism amplifies the inflammatory response. Genes Immun., 2002, 3, 123-135.
99. Jang, Y.; Kim, J.Y.; Kang, S.M.; Kim, J.S.; Chae, J.S.; Kim, O.Y.; Koh, S.J.; Lee, H.C.; Ahn, C.W.; Song, Y.D.; Lee, J.H. Association of the Gly82Ser polymorphism in the receptor for advanced glycation end products (RAGE) gene with circulating levels of soluble RAGE and inflammatory markers in nondiabetic and nonobese Koreans. Metabolism, 2007, 56, 199-205.
100. Li, K.; Dai, D.; Zhao, B.; Yao, L.; Yao, S.; Wang, B.; Yang, Z. Association between the RAGE G82S polymorphism and Alzheimer's disease. J. Neural Transm., 2010, 117, 97-104.
101. Tiszlavicz, Z.; Gyulai, Z.; Bencsik, K.; Szolnoki, Z.; Kocsis, A.K.; Somogyvári, F.; Vécsei, L.; Mándi, Y. RAGE gene polymorphisms in patients with multiple sclerosis. J. Mol. Neurosci., 2009, 39, 360-365.
102. Beisswenger, P.J.; Howell, S.K.; Nelson, R.G.; Mauer, M.; Szwergold, B.S. Alpha-oxoaldehyde metabolism and diabetic complications. Biochem. Soc. Trans., 2003, 31, 1358-1363.
103. Sidoti, A.; Antognelli, C.; Rinaldi, C.; D'Angelo, R.; Dattola, V.; Girlanda, P.; Talesa, V.; Amato, A. Glyoxalase I A111E, paraoxonase 1 Q192R and L55M polymorphisms: susceptibility factors of multiple sclerosis? Mult. Scler., 2007 13 446-453.
104. Vucic, S.; Kiernan, M.C. Pathophysiology of neurodegeneration in familial amyotrophic lateral sclerosis. Curr. Mol. Med., 2009, 9, 255-272.
105. Takazawa, T.; Ikeda, K.; Hirayama, T.; Kawabe, K.; Nakamura, Y.; Ito, H.; Kano, O.; Yoshii, Y.; Tanaka, F.; Sobue, G.; Iwasaki, Y. Familial amyotrophic lateral sclerosis with a novel G85S mutation of superoxide dismutase 1 gene: clinical features of lower motor neuron disease. Intern. Med., 2010, 49, 183-186.
106. Gonsette, R.E. Neurodegeneration in multiple sclerosis: the role of oxidative stress and excitotoxicity. J. Neurol. Sci., 2008, 274 48-53.
107. Lassmann, H. Axonal injury in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry, 2003, 74, 695-697.
108. Bizzozero, O.A.; DeJesus, G.; Callahan, K.; Pastuszyn, A. Elevated protein carbonylation in the brain white matter and gray matter of patients with multiple sclerosis. J. Neurosci. Res., 2005, 81, 687-695.
109. Liu, J.S.; Zhao, M.L,; Brosnan, C.F.; Lee, S.C. Expression of inducible nitric oxide synthase and nitrotyrosine in multiple sclerosis lesions. Am. J. Pathol., 2001, 158, 2057-2066.
110. Vladimirova, O.; O'Connor, J.; Cahill, A.; Alder, H.; Butunoi, C.; Kalman, B. Oxidative damage to DNA in plaques of MS brains. Mult. Scler., 1998, 4, 413-418.
111. Hunter, M.I.; Nlemadim, B.C.; Davidson, D.L. Lipid peroxidation products and antioxidant proteins in plasma and cerebrospinal fluid from multiple sclerosis patients. Neurochem. Res., 1985, 10, 1645-1652.
112. Calabrese, V.; Raffaele, R.; Cosentino, E.; Rizza, V. Changes in cerebrospinal fluid levels of malondialdehyde and glutathione reductase activity in multiple sclerosis. Int. J. Clin. Pharmacol. Res., 1994, 14, 119-123.
113. Naidoo, R, Knapp, M.L. Studies of lipid peroxidation products in cerebrospinal fluid and serum in multiple sclerosis and other conditions. Clin. Chem., 1992, 38, 2449-2454.
114. Newcombe, J.; Li, H.; Cuzner, M.L. Low density lipoprotein uptake by macrophages in multiple sclerosis plaques: implications for pathogenesis. Neuropathol. Appl. Neurobiol., 1994, 20, 152-162.
115. Shukla, V.K.; Jensen, G.E.; Clausen, J. Erythrocyte glutathione perioxidase deficiency in multiple sclerosis. Acta Neurol. Scand., 1977, 56, 542-550.
116. Jensen, G.E.; Clausen, J. Glutathione peroxidase and reductase, glucose-6-phosphate dehydrogenase and catalase activities in multiple sclerosis. J. Neurol. Sci., 1984, 63, 45-53.
117. Langemann, H.; Kabiersch, A.; Newcombe, J. Measurement of low-molecular-weight antioxidants, uric acid, tyrosine and tryptophan in plaques and white matter from patients with multiple sclerosis. Eur. Neurol., 1992, 32, 248-252.
118. Yan, S.S.; Wu, Z.Y.; Zhang, H.P.; Furtado, G.; Chen, X.; Yan, S.F.; Schmidt, A.M.; Brown, C.; Stern, A.; LaFaille, J.; Chess, L.; Stern, D.M.; Jiang, H. Suppression of experimental autoimmune encephalomyelitis by selective blockade of encephalitogenic T-cell infiltration of the central nervous system. Nat. Med., 2003, 9, 287-293.
119. Sternberg, Z.; Weinstock-Guttman, B.; Hojnacki, D.; Zamboni, P.; Zivadinov, R.; Chadha, K.; Lieberman, A.; Kazim, L.; Drake, A.; Rocco, P.; Grazioli, E.; Munschauer, F. Soluble receptor for advanced glycation end products in multiple sclerosis: a potential marker of disease severity. Mult. Scler., 2008, 14, 759-763.
120. Thessen Hedreul, M.; Gillett, A.; Olsson, T.; Jagodic, M.; Harris, R.A. Characterization of Multiple Sclerosis candidate gene expression kinetics in rat experimental autoimmune encephalomyelitis. J. Neuroimmunol., 2009, 29, 30-39.
121. Abdul-Majid, K.B.; Jirholt, J.; Stadelmann, C.; Stefferl, A.; Kjellén, P.; Wallström, E.; Holmdahl, R.; Lassmann, H.; Olsson, T.; Harris, R.A. Screening of several H-2 congenic mouse strains identified H-2(q) mice as highly susceptible to MOG-induced EAE with minimal adjuvant requirement. J. Neuroimmunol., 2000, 111, 23-33.
122. Brett, R.; Rumsby, M.G. Evidence of free radical damage in the central nervous system of guinea-pigs at the prolonged acute and early relapse stages of chronic relapsing experimental allergic encephalomyelitis. Neurochem. Int., 1993, 23, 35-44.
123. Ruuls, S.R.; Bauer, J.; Sontrop, K.; Huitinga, I,; Hart, B.A,; Dijkstra, C.D. Reactive oxygen species are involved in the pathogenesis of experimental allergic encephalomyelitis in Lewis rats. J. Neuroimmunol., 1995, 56, 207-217.
124. van der Veen, R.C.; Hinton, D.R.; Incardonna, F.; Hofman F.M. Extensive peroxynitrite activity during progressive stages of central nervous system inflammation. J Neuroimmunol., 1997, 77, 1-7.
125. Wållberg, M.; Bergquist, J.; Achour, A.; Breij, E.; Harris, R.A. Malondialdehyde modification of myelin oligodendrocyte glycoprotein leads to increased immunogenicity and encephalitogenicity. Eur. J. Immunol., 2007, 37, 986-995.
126. Huizinga, R.; Gerritsen, W.; Heijmans, N.; Amor, S. Axonal loss and gray matter pathology as a direct result of autoimmunity to neurofilaments. Neurobiol. Dis., 2008, 32, 461-470.
127. Huizinga, R.; Heijmans, N.; Schubert, P.; Gschmeissner, S.; 't Hart, BA.; Herrmann, H.; Amor, S. Immunization with neurofilament light protein induces spastic paresis and axonal negeneration in Biozzi ABH mice. J. Neuropathol. Exp. Neurol., 2007, 66, 295-304.
128. Smerjac, S.M.; Bizzozero, O.A. Cytoskeletal protein carbonylation and degradation in experimental autoimmune encephalomyelitis. J. Neurochem., 2008, 105, 763-772.
129. Pamplona, R.; Dalfó, E.; Ayala, V.; Bellmunt, M.J.; Prat, J.; Ferrer, I.; Portero-Otín, M. Proteins in human brain cortex are modified by oxidation, glycoxidation, and lipoxidation: effects of Alzheimer disease and identification of lipoxidation targets. J. Biol. Chem., 2005, 280, 21522-21530.
130. Hensley, K.; Hall, N.; Subramaniam, R.; Cole, P.; Harris, M.; Aksenov, M.; Aksenova, M.; Gabbita, S.P.; Wu, J.F.; Carney, J.M.; Lovell, M.; Markesbery, W.R.; Butterfield, D.A. Brain regional correspondence between Alzheimer's disease histopathology and biomarkers of protein oxidation. J. Neurochem., 1995, 65, 2146-2156.
131. Butterfield, D.A.; Castegna, A.; Lauderback, C.M.; Drake, J. Evidence that amyloid beta-peptide-induced lipid peroxidation and its sequelae in Alzheimer's disease brain contribute to neuronal death. Neurobiol. Aging, 2002, 23, 655-664.
132. Mark, R.J.; Pang, Z.; Geddes, J.W.; Uchida, K.; Mattson, M.P. Amyloid beta-peptide impairs glucose transport in hippocampal and cortical neurons: involvement of membrane lipid peroxidation. J. Neurosci., 1997, 17, 1046-1054.
133. Selley, M.L.; Close, D.R.; Stern, S.E. The effect of incr eased concentrations of homocysteine on the concentration of (E)-4- hydroxy-2-nonenal in the plasma and cerebrospinal fluid of patients with Alzheimer's disease. Neurobiol. Aging, 2002, 23, 383-388.
134. Markesbery, W.R.; Lovell, M.A. Four-hydroxynonenal, a product of lipid peroxidation, is increased in the brain in Alzheimer's disease. Neurobiol. Aging, 1998, 19, 33-36.
135. Arlt, S.; Beisiegel, U.; Kontush, A. Lipid peroxidation in neurodegeneration: new insights into Alzheimer's disease. Curr. Opin. Lipidol., 2002, 13, 289-294.
136. Bradley MA, Markesbery WR, Lovell MA Increased levels of 4- hydroxynonenal and acrolein in the brain in preclinical Alzheimer disease. Free Radic. Biol. Med., 2010, 48, 1570-1576.
137. Mattson, M.P.; Chan, S.L. Neuronal and glial calcium signaling in Alzheimer's disease. Cell Calcium, 2003, 34, 385-397.
138. Deane, R.; Wu, Z.; Zlokovic, B.V. RAGE (yin) versus LRP (yang) balance regulates alzheimer amyloid beta-peptide clearance through transport across the blood-brain barrier. Stroke, 2004, 11S, 2628-2631.
139. Donahue, J.E.; Flaherty, S.L.; Johanson, C.E.; Duncan, J.A; Silverberg, G.D.; Miller, M.C.; Tavares, R.; Yang, W.; Wu, Q.; Sabo, E.; Hovanesian, V.; Stopa, E.G. RAGE, LRP-1, and amyloidbeta protein in Alzheimer's disease. Acta Neuropathol., 2006, 112, 405-415.
140. Sasaki, N.; Toki, S.; Chowei, H.; Saito, T.; Nakano, N.; Hayashi, Y.; Takeuchi, M.; Makita, Z. Immunohistochemical distribution of the receptor for advanced glycation end products in neurons and astrocytes in Alzheimer's disease. Brain Res., 2001, 888, 256-262.
141. Miller, M.C.; Tavares, R.; Johanson, C.E.; Hovanesian, V.; Donahue, J.E.; Gonzalez, L.; Silverberg, G.D.; Stopa, E.G. Hippocampal RAGE immunoreactivity in early and advanced lzheimer's disease. Brain Res., 2008, 1230, 273-280.
142. Wang, M.Y.; Ross-Cisneros, F.N.; Aggarwal, D.; Liang, C.Y.; Sadun, A.A. Receptor for advanced glycation end products is upregulated in optic neuropathy of Alzheimer's disease. Acta Neuropathol., 2009, 118, 381-389.
143. Emanuele, E.; D'Angelo, A.; Tomaino, C.; Binetti, G.; Ghidoni, R.; Politi, P.; Bernardi, L.; Maletta, R.; Bruni, A.C.; Geroldi, D. Circulating levels of soluble receptor for advanced glycation end products in Alzheimer disease and vascular dementia. Arch. Neurol., 2005, 62, 1734-1736.
144. Colaco, C.A.; Harrington, C.R. Glycation: a pathological modification in neuropathies? a hypothesis. Neuroreport, 1994, 5, 859-861.
145. Smith, M.A.; Sayre, L.M.; Monnier, V.M.; Perry, G. Radical AGEing in Alzheimer's disease. Trends Neurosci., 1995, 18 172-176.
146. Sasaki, N.; Fukatsu, R.; Tsuzuki, K.; Hayashi, Y.; Yoshida, T.; Fujii, N.; Koike, T.; Wakayama, I.; Yanagihara, R.; Garruto, R.; Amano, N.; Makita, Z. Advanced glycation end products in Alzheimer's disease and other neurodegenerative diseases. Am. J. Pathol., 1998, 153, 1149-1155.
147. Yan, S.D.; Yan, S.F.; Chen, X.; Fu, J.; Chen, M.; Kuppusamy, P.; Smith, M.A.; Perry, G.; Godman, G.C.; Nawroth, P.; Zweier, J.L.; Stern, D. Non-enzymatically glycated tau in Alzheimer's disease induces neuronal oxidant stress resulting in cytokine gene expression and release of amyloid beta-peptide. Nat. Med., 1995, 1, 693-699.
148. Rossi, F.; Bianchini, E. Synergistic induction of nitric oxide by beta-amyloid and cytokines in astrocytes. Biochem. Biophys. Res. Commun., 1996, 225, 474-478.
149. Lue, L.F.; Walker, D.G.; Brachova, L.; Beach, T.G.; Rogers, J.; Schmidt, A.M.; Stern, D.M.; Yan, S.D. Involvement of microglial receptor for advanced glycation endproducts (RAGE) in Alzheimer's disease: identification of a cellular activation mechanism. Exp. Neurol., 2001, 171, 29-45.
150. Salminen, A.; Kaarniranta, K. Siglec receptors and hiding plaques in Alzheimer's disease. J. Mol. Med., 2009, 87, 697-701.
151. Frank-Cannon, T.C.; Alto, L.T.; McAlpine, F.E.; Tansey, M.G. Does neuroinflammation fan the flame in neurodegenerative diseases? Mol. Neurodegener., 2009, 4, 47.
152. Fang, F.; Lue, L.F.; Yan, S.; Xu, H.; Luddy, J.S.; Chen, D.; Walker, D.G.; Stern, D.M.; Yan, S.; Schmidt, A.M.; Chen, J.X.; Yan, S.S. RAGE-dependent signaling in microglia contributes to neuroinflammation, Abeta accumulation, and impaired learning/memory in a mouse model of Alzheimer's disease. FASEB J., 2010, 24, 1043-1055.
153. Albers, D.S.; Augood, S.J. New insights into progressive supranuclear palsy. Trends Neurosci., 2001, 24, 347-353.
154. Odetti, P.; Garibaldi, S.; Norese, R.; Angelini, G.; Marinelli, L.; Valentini, S.; Menini, S.; Traverso, N.; Zaccheo, D.; Siedlak, S.; Perry, G.; Smith, M.A.; Tabaton, M. Lipoperoxidation is selectively involved in progressive supranuclear palsy. J. Neuropathol. Exp. Neurol., 2000, 59, 393-397.
155. Martínez, A.; Dalfó, E.; Muntané, G.; Ferrer, I. Glycolitic enzymes are targets of oxidation in aged human frontal cortex and oxidative damage of these proteins is increased in progressive supranuclear palsy. J. Neural. Transm., 2008, 115, 59-66.
156. Fitzmaurice, P.S.; Ang, L.; Guttman, M.; Rajput, A.H.; Furukawa, Y.; Kish, S.J. Nigral glutathione deficiency is not specific for idiopathic Parkinson's disease. Mov. Disord., 2003, 18, 969-976.
157. Aoyama, K.; Matsubara, K.; Kobayashi, S. Aging and oxidative stress in progressive supranuclear palsy. Eur. J. Neurol., 2006, 13, 89-92.
158. Lotharius, J.; Brundin P. Pathogenesis of Parkinson's disease: dopamine, vesicles and alpha-synuclein. Nat. Rev. Neurosci., 2002, 3, 932-942.
159. Fahn, S.; Cohen, G. The oxidant stress hypothesis in Parkinson's disease: evidence supporting it. Ann. Neurol., 1992, 32, 804-808.
160. Jenner, P. Oxidative stress in Parkinson's disease. Ann. Neurol., 2003, 53(Suppl 3), S26-36.
161. Adibhatla, R.M.; Hatcher, J.F. Lipid oxidation and peroxidation in CNS health and disease: from molecular mechanisms to therapeutic opportunities. Antioxid. Redox. Signal., 2010, 12, 125-169.
162. Dexter, D.T.; Carter, C.J.; Wells, F.R.; Javoy-Agid, F.; Agid, Y.; Lees, A.; Jenner, P.; Marsden, C.D. Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J. Neurochem., 1989, 52, 381-389.
163. Yoritaka, A.; Hattori, N.; Uchida, K.; Tanaka, M.; Stadtman, E.R.; Mizuno, Y. Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. Proc. Natl. Acad. Sci. USA, 1996, 93, 2696-2701
164. Castellani, R.J.; Perry, G.; Siedlak, S.L.; Nunomura, A.; Shimohama, S.; Zhang, J.; Montine, T.; Sayre, L.M.; Smith, M.A. Hydroxynonenal adducts indicate a role for lipid peroxidation in neocortical and brainstem Lewy bodies in humans. Neurosci. Lett., 2002, 319, 25-28
165. Mariani, E.; Polidori, M.C.; Cherubini, A.; Mecocci, P. Oxidative stress in brain aging, neurodegenerative and vascular diseases: an overview. J. Chromatogr. B. Analyt. Technol. Biomed. Life. Sci., 2005, 827, 65-75.
166. Floor, E.; Wetzel, M.G. Increased protein oxidation in human substantia nigra pars compacta in comparison with basal ganglia and prefrontal cortex measured with an improved dinitrophenylhydrazine assay. J. Neurochem., 1998, 70, 268-275.
167. Alam, Z.I.; Jenner, A.; Daniel, S.E.; Lees, A.J.; Cairns, N.; Marsden, C.D.; Jenner, P.; Halliwell, B. Oxidative DNA damage in the parkinsonian brain: an apparent selective increase in 8- hydroxyguanine levels in substantia nigra. J. Neurochem., 1997, 69, 1196-1203.
168. Hunot, S.; Dugas, N.; Faucheux, B.; Hartmann, A.; Tardieu, M.; Debré, P.; Agid, Y.; Dugas, B.; Hirsch, E.C. FcepsilonRII/CD23 is expressed in Parkinson's disease and induces, in vitro, production of nitric oxide and tumor necrosis factor-alpha in glial cells. J. Neurosci., 1999, 19, 3440-3447.
169. Duda, J.E.; Giasson, B.I.; Chen, Q.; Gur, T.L.; Hurtig, H.I.; Stern, M.B.; Gollomp, S.M.; Ischiropoulos, H.; Lee, V.M.; Trojanowski, J.Q. Widespread nitration of pathological inclusions in neurodegenerative synucleinopathies. Am. J. Pathol., 2000, 157, 1439-1445.
170. Giasson, B.I.; Duda, J.E.; Murray, I.V.; Chen, Q.; Souza, J.M.; Hurtig, H.I.; Ischiropoulos, H.; Trojanowski, J.Q.; Lee, V.M. Oxidative damage linked to neurodegeneration by selective alpha- synuclein nitration in synucleinopathy lesions. Science, 2000, 290, 985-989.
171. Calabrese, V.; Guagliano, E.; Sapienza, M.; Mancuso, C.; Butterfield, D.A.; Stella, A.M. Redox regulation of cellular stress response in neurodegenerative disorders. Ital. J. Biochem., 2006, 55, 263-282.
172. Ma, L.; Nicholson, L.F. Expression of the receptor for advanced glycation end products in Huntington's disease caudate nucleus. Brain Res., 2004, 1018, 10-17.
173. Julien, J.P. Amyotrophic lateral sclerosisunfolding the toxicity of the misfolded. Cell, 2001, 104, 581-591.
174. Shibata, N.; Nagai, R.; Uchida, K.; Horiuchi, S.; Yamada, S.; Hirano, A.; Kawaguchi, M.; Yamamoto, T.; Sasaki, S.; Kobayashi, M. Morphological evidence for lipid peroxidation and protein glycoxidation in spinal cords from sporadic amyotrophic lateral sclerosis patients. Brain Res., 2001, 917, 97-104.
175. Ferrante, R.J.; Browne, S.E.; Shinobu, L.A.; Bowling, A.C.; Baik, M.J.; MacGarvey, U.; Kowall, N.W.; Brown, R.H.; Beal, M.F. Evidence of increased oxidative damage in both sporadic and familial amyotrophic lateral sclerosis. J. Neurochem., 1997, 69, 2064-2074.
176. Shaw, P.J.; Ince, P.G.; Falkous, G.; Mantle, D. Oxidative damage to protein in sporadic motor neuron disease spinal cord. Ann. Neurol., 1995, 38, 691-695.
177. Pedersen, W.A.; Fu, W.; Keller, J.N.; Markesbery, W.R.; Appel, S.; Smith, R.G.; Kasarskis, E.; Mattson, M.P. Protein modification by the lipid peroxidation product 4-hydroxynonenal in the spinal cords of amyotrophic lateral sclerosis patients. Ann. Neurol., 1998, 44, 819-824.
178. Rothstein, J.D.; Van Kammen, M.; Levey, A.I.; Martin, L.J.; Kuncl, R.W. Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann. Neurol., 1995, 38, 73-84.
179. Shibata, T.; Iio, K.; Kawai, Y.; Shibata, N.; Kawaguchi, M.; Toi, S.; Kobayashi, M.; Kobayashi, M.; Yamamoto, K.; Uchida, K. Identification of a lipid peroxidation product as a potential trigger of the p53 pathway. J. Biol. Chem., 2006, 281, 1196-1204.
180. I zecka, J. Serum-soluble receptor for advanced glycation end product levels in patients with amyotrophic lateral sclerosis. Acta Neurol. Scand., 2009, 120, 119-122.
181. Moreau, C.; Devos, D.; Brunaud-Danel, V.; Defebvre, L.; Perez, T.; Destée, A.; Tonnel, A.B.; Lassalle, P.; Just, N. Elevated IL-6 and TNF-alpha levels in patients with ALS: inflammation or hypoxia? Neurology, 2005, 65, 1958-1960.
182. Adibhatla, R.M.; Hatcher, J.F. Altered lipid metabolism in brain injury and disorders. Subcell. Biochem., 2008, 49, 241-268.
183. Kimura, T.; Ikeda, K.; Takamatsu, J.; Miyata, T.; Sobue, G.; Miyakawa, T.; Horiuchi, S. Identification of advanced glycation end products of the Maillard reaction in Pick's disease. Neurosci. Lett., 1996, 219, 95-88.
184. Reddy, JV.; Ganley, I.G.; Pfeffer, S.R. Clues to neuro-degeneration in Niemann-Pick type C disease from global gene expression profiling. PLoS One, 2006, 1, e19.
185. Hartzler, A.W.; Zhu, X.; Siedlak, S.L.; Castellani, R.J.; Avilá, J.; Perry, G.; Smith, M.A. The p38 pathway is activated in Pick disease and progressive supranuclear palsy: a mechanistic link between mitogenic pathways, oxidative stress, and tau. Neurobiol. Aging, 2002, 23, 855-859.
186. Krapfenbauer, K.; Engidawork, E.; Cairns, N.; Fountoulakis, M.; Lubec, G. Aberrant expression of peroxiredoxin subtypes in neurodegenerative disorders. Brain Res., 2003, 967, 152-160.
187. Sasaki, N.; Fukatsu, R.; Tsuzuki, K.; Hayashi, Y.; Yoshida, T.; Fujii, N.; Koike, T.; Wakayama, I.; Yanagihara, R.; Garruto, R.; Amano, N.; Makita, Z. Advanced glycation end products in Alzheimer's disease and other neurodegenerative diseases. Am. J. Pathol., 1998, 153, 1149-1155.
188. Montine, K.S.; Kim, P.J.; Olson, S.J.; Markesbery, W.R.; Montine, T.J. 4-hydroxy-2-nonenal pyrrole adducts in human neurodegenerative disease. J. Neuropathol. Exp. Neurol., 1997, 56, 866-871.
189. Muntané, G.; Dalfó, E.; Martínez, A.; Rey, M.J.; Avila, J.; Pérez, M.; Portero, M.; Pamplona, R.; Ayala, V.; Ferrer, I. Glial fibrillary acidic protein is a major target of glycoxidative and lipoxidative damage in Pick's disease. J. Neurochem., 2006, 99, 177-185.
190. Haugen, A.C.; Di Prospero, N.A.; Parker, J.S.; Fannin, R.D.; Chou, J.; Meyer, J.N.; Halweg, C.; Collins, J.B.; Durr, A.; Fischbeck, K.; Van Houten, B. Altered gene expression and DNA damage in peripheral blood cells from Friedreich's ataxia patients: cellular model of pathology. PLoS Genet., 2010, 6, e1000812.
191. Santos, R.; Lefevre, S.; Sliwa, D.; Seguin, A.; Camadro, J.M.; Lesuisse, E. Friedreich's ataxia; molecular mechanisms, redox consideration and therapeutic opportunities. Antioxid. Redox. Signal., 2010, (in press).
192. Bradley, J.L.; Homayoun, S.; Hart, P.E.; Schapira, A.H.; Cooper, J.M. Role of oxidative damage in Friedreich's ataxia. Neurochem. Res., 2004, 29, 561-567.
193. Emond, M.; Lepage, G.; Vanasse, M.; Pandolfo, M. Increased levels of plasma malondialdehyde in Friedreich ataxia. Neurology, 2000, 55, 1752-1753.
194. Armstrong, J.S.; Khdour, O.; Hecht, S.M. Does oxidative stress contribute to the pathology of Friedreich's ataxia? A radical question. FASEB J., 2010, (in press).
195. Rustin, P.; von Kleist-Retzow, J.C.; Chantrel-Groussard, K.; Sidi, D.; Munnich, A.; Rötig, A. Effect of idebenone on cardiomyopathy in Friedreich's ataxia: a preliminary study. Lancet, 1999, 354, 477-479.
196. Puccio, H. Multicellular models of Friedreich ataxia. J. Neurol., 2009, 256(Suppl 1), 18-24.
197. Lu, C.; Schoenfeld, R.; Shan, Y.; Tsai, H.J.; Hammock, B.; Cortopassi, G. Frataxin deficiency induces Schwann cell inflammation and death. Biochim. Biophys. Acta, 2009, 1792, 1052-1061.
198. Prusiner, S.B. Shattuck lecture--neurodegenerative diseases and prions. N. Engl. J. Med., 2001, 344, 1516-1526.
199. Arlt, S.; Kontush, A.; Zerr, I.; Buhmann, C.; Jacobi, C.; Schröter, A.; Poser, S.; Beisiegel, U. Increased lipid peroxidation in cerebrospinal fluid and plasma from patients with Creutzfeldt- Jakob disease. Neurobiol. Dis., 2002, 10, 150-156.
200. Negre-Salvayre, A.; Coatrieux, C.; Ingueneau, C.; Salvayre, R. Advanced lipid peroxidation end products in oxidative damage to proteins. Potential role in diseases and therapeutic prospects for the inhibitors. Br. J. Pharmacol., 2008, 153, 6-20.
201. Sasaki, N.; Takeuchi, M.; Chowei, H.; Kikuchi, S.; Hayashi, Y.; Nakano, N.; Ikeda, H.; Yamagishi, S.; Kitamoto, T.; Saito, T.; Makita, Z. Advanced glycation end products (AGE) and their receptor (RAGE) in the brain of patients with Creutzfeldt-Jakob disease with prion plaques. Neurosci. Lett., 2002, 326, 117-120.
202. Freixes, M.; Rodríguez, A.; Dalfó, E.; Ferrer, I. Oxidation, glycoxidation, lipoxidation, nitration, and responses to oxidative stress in the cerebral cortex in Creutzfeldt-Jakob disease. Neurobiol. Aging, 2006, 27, 1807-1815.
203. Pamplona, R.; Naudí, A.; Gavín, R.; Pastrana, M.A.; Sajnani, G.; Ilieva, E.V.; Del Río, J.A.; Portero-Otín, M.; Ferrer, I.; Requena, J.R. Increased oxidation, glycoxidation, and lipoxidation of brain proteins in prion disease. Free Radic. Biol. Med., 2008, 45, 1159-1166.
204. Sousa, M.M.; Saraiva, M.J. Neurodegeneration in familial amyloid polyneuropathy: from pathology to molecular signaling. Prog. Neurobiol., 2003, 71, 385-400.
205. Sousa, M.M.; Du Yan, S.; Fernandes, R.; Guimaraes, A.; Stern, D.; Saraiva, M.J. Familial amyloid polyneuropathy: receptor for advanced glycation end products-dependent triggering of neuronal inflammatory and apoptotic pathways. J. Neurosci., 2001, 21, 7576-7586.
206. Bierhaus, A.; Haslbeck, K.M.; Humpert, P.M.; Liliensiek, B.; Dehmer, T.; Morcos, M.; Sayed, A.A.; Andrassy, M.; Schiekofer, S.; Schneider, J.G.; Schulz, J.B.; Heuss, D.; Neundörfer, B.; Dierl, S.; Huber, J.; Tritschler, H.; Schmidt, A.M.; Schwaninger, M.; Haering, H.U.; Schleicher, E.; Kasper, M.; Stern, D.M.; Arnold, B.; Nawroth, P.P. Loss of pain perception in diabetes is dependent on a receptor of the immunoglobulin superfamily. J. Clin. Invest., 2004, 114, 1741-1751
207. Ando, Y.; Nyhlin, N.; Suhr, O.; Holmgren, G.; Uchida, K.; el Sahly, M.; Yamashita, T.; Terasaki, H.; Nakamura, M.; Uchino, M.; Ando, M. Oxidative stress is found in amyloid deposits in systemic amyloidosis. Biochem. Biophys. Res. Commun., 1997, 232, 497-502.
208. Gomes, R.; Sousa Silva, M.; Quintas, A.; Cordeiro, C.; Freire, A.; Pereira, P.; Martins, A.; Monteiro, E.; Barroso, E.; Ponces Freire, A. Argpyrimidine, a methylglyoxal-derived advanced glycation end-product in familial amyloidotic polyneuropathy. Biochem. J., 2005, 385, 9-45.
209. Power, J.H.; Blumbergs, P.C. Cellular glutathione peroxidase in human brain: cellular distribution, and its potential role in the degradation of Lewy bodies in Parkinson's disease and dementia with Lewy bodies. Acta Neuropathol., 2009, 117, 63-73.
210. Navarro, A.; Boveris, A.; Bández, M.J.; Sánchez-Pino, M.J.; Gómez, C.; Muntané, G.; Ferrer, I. Human brain cortex: mitochondrial oxidative damage and adaptive response in Parkinson disease and in dementia with Lewy bodies. Free Radic. Biol. Med., 2009 46, 1574-1580.
211. Crack, P.J.; Taylor, J.M.; Flentjar, N.J.; de Haan, J.; Hertzog, P.; Iannello, R.C.; Kola, I. Increased infarct size and exacerbated apoptosis in the glutathione peroxidase-1 (Gpx-1) knockout mouse brain in response to ischemia/reperfusion injury. J. Neurochem., 2001, 78, 1389-1399.
212. Hamanishi, T.; Furuta, H.; Kato, H.; Doi, A.; Tamai, M.; Shimomura, H.; Sakagashira, S.; Nishi, M.; Sasaki, H.; Sanke, T.; Nanjo, K. Functional variants in the glutathione peroxidase-1 (GPx-1) gene are associated with increased intima-media thickness of carotid arteries and risk of macrovascular diseases in Japanese type 2 diabetic patients. Diabetes, 2004, 3, 2455-2460.
213. Dalfó, E.; Portero-Otín, M.; Ayala, V.; Martínez, A.; Pamplona, R.; Ferrer, I. Evidence of oxidative stress in the neocortex in incidental Lewy body disease. J. Neuropathol. Exp. Neurol., 2005, 64, 816-830.
214. Andreazza, A.C.; Kauer-Sant'anna, M.; Frey, B.N.; Bond, D.J.; Kapczinski, F.; Young, L.T.; Yatham, L.N. Oxidative stress markers in bipolar disorder: a meta-analysis. J. Affect. Disord., 2008 111, 135-144.
215. Kunz, M.; Gama, C.S.; Andreazza, A.C.; Salvador, M.; Ceresér, K.M.; Gomes, F.A.; Belmonte-de-Abreu, P.S.; Berk, M.; Kapczinski, F. Elevated serum superoxide dismutase and thiobarbituric acid reactive substances in different phases of bipolar disorder and in schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2008, 32, 1677-1681.
216. Wang, J.F.; Shao, L.; Sun, X.; Young, L.T. Increased oxidative stress in the anterior cingulate cortex of subjects with bipolar disorder and schizophrenia. Bipolar Disord., 2009, 11, 523-529.
217. Rezin, G.T.; Amboni, G.; Zugno, A.I.; Quevedo, J.; Streck, E.L. Mitochondrial dysfunction and psychiatric disorders. Neurochem. Res., 2009, 34, 1021-1029.
218. Waldbaum, S.; Patel, M. Mitochondria, oxidative stress, and temporal lobe epilepsy. Epilepsy Res., 2010, 88, 23-45.
219. Freitas, R.M. Investigation of oxidative stress involvement in hippocampus in epilepsy model induced by pilocarpine. Neurosci. Lett., 2009, 462, 225-229.
220. Deepa, D.; Jayakumari, B.; Thomas, S.V. Lipid peroxidation in women with epilepsy. Ann. Indian Acad. Neurol., 2008 11, 44-46
221. Yi, U.; Seçkin, E.; Kurul, S.H.; Kuralay, F.; Dirik, E. Effects of epilepsy and valproic acid on oxidant status in children with idiopathic epilepsy. Epilepsy Res., 2009, 84, 232-237.
222. Aycicek, A.; Iscan, A Oxidative and antioxidative capacity in children with cerebral palsy. Brain Res. Bull., 2006, 69, 666-668.
223. Odetti, P.; Angelini, G.; Dapino, D.; Zaccheo, D.; Garibaldi, S.; Dagna-Bricarelli, F.; Piombo, G.; Perry, G.; Smith, M.; Traverso, N.; Tabaton, M. Early glycoxidation damage in brains from Down's syndrome. Biochem. Biophys. Res. Commun., 1998, 243, 849-851.
224. Kaufmann, E.; Boehm, B.O.; Süssmuth, S.D.; Kientsch-Engel, R.; Sperfeld, A.; Ludolph, A.C.; Tumani, H. The advanced glycation end-product N epsilon-(carboxymethyl)lysine level is elevated in cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Neurosci. Lett., 2004, 371, 226-229.
225. Zimmerman, G.A.; Meistrell, M.; Bloom, O.; Cockroft, K.M.; Bianchi, M.; Risucci, D.; Broome, J.; Farmer, P.; Cerami A.; Vlassara, H.; Tracey, K. Neurotoxicity of advanced glycation endproducts during focal stroke and neuroprotective effects of aminoguanidine. Proc. Natl. Acad. Sci. USA, 1995, 92, 3744-3748.
226. Kögel, D.; Peters, M.; König, H.G.; Hashemi, S.M.; Bui, N.T.; Arolt, V.; Rothermundt, M.; Prehn, J.H. S100B potently activates p65/c-Rel transcriptional complexes in hippocampal neurons: Clinical implications for the role of S100B in excitotoxic brain injury. Neuroscience, 2004, 127, 913-920.
227. Yokota, C.; Minematsu, K.; Tomii, Y.; Naganuma, M.; Ito, A.; Nagasawa, H.; Yamaguchi, T. Low levels of plasma soluble receptor for advanced glycation end products are associated with severe leukoaraiosis in acute stroke patients. J. Neurol. Sci., 2009, 287, 41-44.
228. Hall, E.D.; Springer, J.E. Neuroprotection and acute spinal cord injury: a reappraisal. NeuroRx., 2004, 1, 80-100.
229. Hall, E.D.; Detloff, M.R.; Johnson, K.; Kupina, N.C. Peroxynitrite- mediated protein nitration and lipid peroxidation in a mouse model of traumatic brain injury. J Neurotrauma., 2004, 21, 9-20.
230. Petronilho, F.; Feier, G.; de Souza, B.; Guglielmi, C.; Constantino, L.S.; Walz, R.; Quevedo, J.; Dal-Pizzol, F. Oxidative stress in brain according to traumatic brain injury intensity. J. Surg. Res., 2009, in press.
231. Bayir, H.; Marion, D.W.; Puccio, A.M.; Wisniewski, S.R.; Janesko, K.L.; Clark, R.S.; Kochanek, P.M. Marked gender effect on lipid peroxidation after severe traumatic brain injury in adult patients. J. Neurotrauma, 2004, 21, 1-8.
232. Xiong, Y.; Hall, E.D. Pharmacological evidence for a role of peroxynitrite in the pathophysiology of spinal cord injury. Exp. Neurol., 2009, 216, 105-114.
233. Ramanan, S.; Zhao, W.; Riddle, D.R.; Robbins, M.E. Role of PPARs in Radiation-Induced Brain Injury. PPAR Res., 2010, 2010, Article ID. 234975.
234. Lolmede, K.; Campana, L.; Vezzoli, M.; Bosurgi, L.; Tonlorenzi, R.; Clementi, E.; Bianchi, M.E.; Cossu, G.; Manfredi, A.A.; Brunelli, S.; Rovere-Querini, P. Inflammatory and alternatively activated human macrophages attract vessel-associated stem cells, relying on separate HMGB1- and MMP-9-dependent pathways. J. Leukoc. Biol., 2009, 85, 779-787.
235. Ma, L.; Carter, R.J.; Morton, A.J.; Nicholson, L.F. RAGE is expressed in pyramidal cells of the hippocampus following moderate hypoxic-ischemic brain injury in rats. Brain Res., 2003, 966, 167-174.
236. Li, J.J.; Surini, M.; Catsicas, S.; Kawashima, E.; Bouras, C. Age- dependent accumulation of advanced glycosylation end products in human neurons. Neurobiol. Aging, 1995, 16, 69-76.
237. Li, J.J.; Voisin, D.; Quiquerez, A.L.; Bouras, C. Differential expression of advanced glycosylation end-products in neurons of different species. Brain Res., 1994, 641, 285-288.
238. Vitek, M.P.; Bhattacharya, K.; Glendening, J.M.; Stopa, E.; Vlassara, H.; Bucala, R.; Manogue, K.; Cerami, A. Advanced glycation end products contribute to amyloidosis in Alzheimer disease. Proc. Natl. Acad. Sci. USA, 1994, 91, 4766-4770.
239. McEwen, J.E.; Zimniak, P.; Mehta JL, Shmookler Reis RJ. Molecular pathology of aging and its implications for senescent coronary atherosclerosis. Curr. Opin. Cardiol., 2005, 20, 399-406.
240. Voss P, Siems W. Clinical oxidation parameters of aging. Free Radic Res., 2006, 40 1339-1349.
241. Stewart WF, Kawas C, Corrada M, Metter EJ.Risk of Alzheimer's disease and duration of NSAID use. Neurology, 1997, 48, 626-632.
242. Kimura T, Takamatsu J, Miyata T, Miyakawa T, Horiuchi S. Localization of identified advanced glycation end-product structures, N epsilon(carboxymethyl)lysine and pentosidine, in agerelated inclusions in human brains. Pathol. Int., 1998, 48, 575-579.
243. Chou DK, Zhang J, Smith FI, McCaffery P, Jungalwala FB. Developmental expression of receptor for advanced glycation end products (RAGE), amphoterin and sulfoglucuronyl (HNK-1) carbohydrate in mouse cerebellum and their role in neurite outgrowth and cell migration. J. Neurochem., 2004, 90, 1389-1401.
244. S Roriz-Filho J, Sá-Roriz TM, Rosset I, Camozzato AL, Santos AC, Chaves ML, Moriguti JC, Roriz-Cruz M. (Pre)diabetes, brain aging, and cognition. Biochim. Biophys. Acta, 2009, 1792, 432-443.
245. Morcos, M.; Du, X.; Pfisterer, F.; Hutter, H.; Sayed, A.A.; Thornalley, P.; Ahmed, N.; Baynes, J.; Thorpe, S.; Kukudov, G.; Schlotterer, A.; Bozorgmehr, F.; El Baki, R.A.; Stern, D.; Moehrlen, F.; Ibrahim, Y.; Oikonomou, D.; Hamann, A.; Becker, C.; Zeier M.; Schwenger, V.; Miftari, N.; Humpert, P.; Hammes, H.P.; Buechler, M.; Bierhaus, A.; Brownlee, M.; Nawroth, P.P. Glyoxalase-1 prevents mitochondrial protein modification and enhances lifespan in Caenorhabditis elegans. Aging Cell, 2008, 7, 260-269.
246. Arbus, C.; Cochen, V.; Sleep changes with aging. Psychol. Neuropsychiatr. Vieil., 2010, 8, 7-14.
247. Brown, M.K.; Naidoo, N. The UPR and the antioxidant response: relevance to sleep and sleep loss. Mol. Neurobiol., 2010, (in press).
248. Brass SD, Duquette P, Proulx-Therrien J, Auerbach SSleep disorders in patients with multiple sclerosis. Sleep Med. Rev., 2010, 14, 121-129.
249. Arnulf I, Merino-Andreu M, Bloch F, Konofal E, Vidailhet M, Cochen V, Derenne JP, Agid Y. REM sleep behavior disorder and REM sleep without atonia in patients with progressive supranuclear palsy. Sleep, 2005, 28, 349-354.
250. Lo Coco D, Caruso G, Mattaliano A. REM sleep behavior disorder in patients with DJ-1 mutations and parkinsonism-dementia-ALS complex. Mov. Disord., 2009, 24, 1555-1556.
251. Goodman AO, Barker RA. How vital is sleep in Huntington's disease? J. Neurol., 2010, 257, 882-897.
252. Vankova, J.; Stepanova, I.; Jech, R.; Elleder, M.; Ling, L.; Mignot, E.; Nishino, S.; Nevsimalova, S. Sleep disturbances and hypocretin deficiency in Niemann-Pick disease type C. Sleep, 2003, 26, 427-430.
253. Limousin, N.; Corcia, P.; Guennoc, A.M.; Lucas, B.; Sazdovitch, V.; Haïk, S.; De Toffol, B.; Praline, J. Sleep disturbances in variant of Creutzfeldt-Jakob disease. Sleep Med., 2009, 10, 690.
254. Salvi, F.; Montagna, P.; Plasmati, R.; Rubboli, G.; Cirignotta, F.; Veilleux, M.; Lugaresi, E.; Tassinari, C.A. Restless legs syndrome and nocturnal myoclonus: initial clinical manifestation of familial amyloid polyneuropathy. J. Neurol. Neurosurg. Psychiatry, 1990, 53, 522-525.
255. Staedt, J.; Hauser, M.; Gudlowski, Y.; Stoppe, G. Sleep disorders in schizophrenia. Fortschr. Neurol. Psychiatr., 2010, 78, 70-80.
256. Parisi, P.; Bruni, O.; Pia Villa, M.; Verrotti, A.; Miano, S.; Luchetti, A.; Curatolo, P. The relationship between sleep and epilepsy: the effect on cognitive functioning in children. Dev. Med. Child. Neurol., 2010, (in press).
257. Biering-Sørensen, F.; Jennum, P.; Laub, M. Sleep disordered breathing following spinal cord injury. Respir. Physiol. Neurobiol., 2009, 169, 165-170.
258. Patten, S.B.; Lauderdale, W.M. Delayed sleep phase disorder after traumatic brain injury. J. Am. Acad. Child Adolesc. Psychiatry, 1992, 31, 100-102.
259. Naidoo, N. The endoplasmic reticulum stress response and aging. Rev Neurosci., 2009, 20, 23-37.
260. Gow A, Sharma R.The unfolded protein response in protein aggregating diseases. Neuromolecular Med., 2003, 4, 73-94.
261. Nishitoh, H.; Matsuzawa, A.; Tobiume, K.; Saegusa, K.; Takeda, K.; Inoue, K.; Hori, S.; Kakizuka, A.; Ichijo, H. ASK1 is essential for endoplasmic reticulum stress-induced neuronal cell death triggered by expanded polyglutamine repeats. Genes Dev., 2002, 16, 1345-1355.
262. Imai, Y.; Soda, M.; Inoue, H.; Hattori, N.; Mizuno, Y.; Takahashi, R. An unfolded putative transmembrane polypeptide, which can lead to endoplasmic reticulum stress, is a substrate of Parkin. Cell, 2001, 105, 891-902.
263. Sitte, N.; Merker, K.; Von Zglinicki, T.; Grune, T.; Davies, K.J. Protein oxidation and degradation during cellular senescence of human BJ fibroblasts: part I--effects of proliferative senescence. FASEB J., 2000, 14, 2495-2502.
264. Berlett, B.S.; Stadtman, E.R. Protein oxidation in aging, disease, and oxidative stress. J. Biol. Chem., 1997, 272, 20313-20316.
265. Aldini, G.; Dalle-Donne, I.; Facino, R.M.; Milzani, A.; Carini, M. Intervention strategies to inhibit protein carbonylation by lipoxidation-derived reactive carbonyls. Med. Res. Rev., 2007, 27, 817-868.
266. Adibhatla, R.M.; Hatcher, J.F. Lipid oxidation and peroxidation in CNS health and disease: from molecular mechanisms to therapeutic opportunities. Antioxid. Redox. Signal., 2010, 12, 125-169.
267. Brownlee, M.; Vlassara, H.; Kooney, A.; Ulrich, P.; Cerami, A. Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science, 1986, 232, 1629-1632.
268. Forbes, J.M.; Yee, L.T.; Thallas, V.; Lassila, M.; Candido, R.; Jandeleit-Dahm, K.A.; Thomas, M.C.; Burns, W.C.; Deemer, E.K.; Thorpe, S.R.; Cooper, M.E.; Allen, T.J. Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis. Diabetes, 2004, 53, 1813-1823.
269. Alderson, N.L.; Chachich, M.E.; Frizzell, N.; Canning, P.; Metz, T.O.; Januszewski, A.S.; Youssef, N.N.; Stitt, A.W.; Baynes, J.W.; Thorpe, S.R. Effect of antioxidants and ACE inhibition on chemical modification of proteins and progression of nephropathy in the streptozotocin diabetic rat. Diabetologia, 2004, 47, 1385-1395.
270. Figarola, J.L.; Scott, S.; Loera, S.; Tessler, C.; Chu, P.; Weiss, L.; Hardy, J.; Rahbar, S. LR-90 a new advanced glycation endproduct inhibitor prevents progression of diabetic nephropathy in streptozotocin-diabetic rats. Diabetologia, 2003, 46, 1140-1152.
271. Candido, R.; Forbes, J.M.; Thomas, M.C.; Thallas, V.; Dean, R.G.; Burns, W.C.; Tikellis C.; Ritchie, R.H.; Twigg, S.M.; Cooper, M.E.; Burrell, L.M. A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes. Circ. Res., 2003, 92, 785-792.
272. Willemsen, S.; Hartog, J.W.; Hummel, Y.M.; Posma, J.L.; van Wijk, L.M.; van Veldhuisen, D.J.; Voors, A.A. Effects of alagebrium, an advanced glycation end-product breaker, in patients with chronic heart failure: study design and baseline characteristics of the BENEFICIAL trial. Eur. J. Heart Fail., 2010, 12, 294-300.
273. de Arriba, S.G.; Krügel, U.; Regenthal, R.; Vissiennon, Z.; Verdaguer, E.; Lewerenz, A.; García-Jordá, E.; Pallas, M.; Camins, A.; Münch, G.; Nieber, K.; Allgaier, C. Carbonyl stress and NMDA receptor activation contribute to methylglyoxal neurotoxicity. Free Radic. Biol. Med., 2006, 40, 779-790.
274. Bro, S.; Flyvbjerg, A.; Binder, C.J.; Bang, C.A.; Denner, L.; Olgaard, K.; Nielsen, L.B. A neutralizing antibody against receptor for advanced glycation end products (RAGE) reduces atherosclerosis in uremic mice. Atherosclerosis, 2008, 201, 274-280.
275. Sturchler, E.; Galichet, A.; Weibel, M.; Leclerc, E.; Heizmann, C.W. Site-specific blockade of RAGE-Vd prevents amyloid-beta oligomer neurotoxicity. J. Neurosci., 2008, 28, 5149-5158.
276. Yamagishi, S.; Nakamura, K.; Matsui, T.; Ueda, S.; Fukami, K.; Okuda, S. Agents that block advanced glycation end product (AGE)-RAGE (receptor for AGEs)-oxidative stress system: a novel therapeutic strategy for diabetic vascular complications. Expert Opin. Investig. Drugs, 2008, 17, 983-996.
277. Matsui, T.; Yamagishi, S.; Takeuchi, M.; Ueda, S.; Fukami, K.; Okuda, S. Nifedipine, a calcium channel blocker, inhibits advanced glycation end product (AGE)-elicited mesangial cell damage by suppressing AGE receptor (RAGE) expression via peroxisome proliferator-activated receptor-gamma activation. Biochem. Biophys. Res. Commun., 2009, 385, 269-272.
278. Cui, X.P.; Li, B.Y.; Gao, H.Q.; Wei, N.; Wang, W.L.; Lu, M. Effects of grape seed proanthocyanidin extracts on peripheral nerves in streptozocin-induced diabetic rats. J. Nutr. Sci. Vitaminol. (Tokyo), 2008, 54, 321-328.
279. Tontonoz, P.; Spiegelman, B.M. Fat and beyond: the diverse biology of PPARgamma. Annu. Rev. Biochem., 2008, 77, 289-312.
280. Heneka, M.T.; Sastre, M.; Dumitrescu-Ozimek, L.; Hanke, A.; Dewachter, I.; Kuiperi, C.; O'Banion, K.; Klockgether, T.; van leuven, f.; Landreth, G.E. Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice. Brain, 2005, 128, 1442-1453.
281. Hirohata, M.; Ono, K.; Naiki, H.; Yamada, M. Non-steroidal anti- inflammatory drugs have anti-amyloidogenic effects for Alzheimer's beta-amyloid fibrils in vitro. Neuropharmacology, 2005, 49, 1088-1099.
282. Kreisler, A.; Gelé, P.; Wiart, J.F.; Lhermitte, M.; Destée, A.; Bordet, R. Lipid-lowering drugs in the MPTP mouse model of Parkinson's disease: fenofibrate has a neuroprotective effect, whereas bezafibrate and HMG-CoA reductase inhibitors do not. Brain Res., 2007, 1135, 77-84.
283. Dehmer, T.; Heneka, M.T.; Sastre, M.; Dichgans, J.; Schulz, J.B. Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with I kappa B alpha induction and block of NF kappa B and iNOS activation. J. Neurochem., 2004, 88, 494-501.
284. Lovett-Racke, A.E.; Hussain, R.Z.; Northrop, S.; Choy, J.; Rocchini, A.; Matthes, L.; Chavis, J.A.; Diab, A.; Drew, P.D.; Racke, M.K. Peroxisome proliferator-activated receptor alpha agonists as therapy for autoimmune disease. J. Immunol., 2004, 172, 5790-5798.
285. Dasgupta, S.; Roy, A.; Jana, M.; Hartley, D.M.; Pahan, K. Gemfibrozil ameliorates relapsing-remitting experimental autoimmune encephalomyelitis independent of peroxisome proliferator-activated receptor-alpha. Mol. Pharmacol., 2007, 72, 934-946.
286. Xia, J.R.; Liu, N.F.; Zhu, N.X. Specific siRNA targeting the receptor for advanced glycation end products inhibits experimental hepatic fibrosis in rats. Int. J. Mol. Sci., 2008, 9, 638-661.
287. Tiemann, K.; Rossi, J.J. RNAi-based therapeutics-current status, challenges and prospects. EMBO Mol. Med., 2009, 1, 142-151.
288. Jang, S.I.; Jeong, S.I.; Kim, K.J.; Kim, H.J.; Yu, H.H.; Park, R.; Kim, H.M.; You, Y.O. Tanshinone IIA from Salvia miltiorrhiza inhibits inducible nitric oxide synthase expression and production of TNF-alpha, IL-1beta and IL-6 in activated RAW 264.7 cells. Planta Med., 2003, 69, 1057-1059.
289. Liliensiek, B.; Weigand, M.A.; Bierhaus, A.; Nicklas, W.; Kasper, M.; Hofer, S.; Plachky, J.; Gröne, H.J.; Kurschus, F.C.; Schmidt, A.M.; Yan, S.D.; Martin, E.; Schleicher, E.; Stern, D.M.; Hämmerling, G.G.; Nawroth, P.P.; Arnold, B. Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response. J. Clin. Invest., 2004, 113, 1641-1650.
290. Yamagishi, S.; Nakamura, K.; Matsui, T.; Inagaki, Y.; Takenaka, K.; Jinnouchi, Y.; Yoshida, Y.; Matsuura, T.; Narama, I.; Motomiya, Y.; Takeuchi, M.; Inoue, H.; Yoshimura, A.; Bucala, R.; Imaizumi, T. Pigment epithelium-derived factor inhibits advanced glycation end product-induced retinal vascular hyperpermeability by blocking reactive oxygen species-mediated vascular endothelial growth factor expression. J. Biol. Chem., 2006, 281, 20213-20220.
291. Jinnouchi, Y.; Yamagishi, S.; Takeuchi, M.; Ishida, S.; Jinnouchi, Y.; Jinnouchi, J.; Imaizumi, T. Atorvastatin decreases serum levels of advanced glycation end products (AGEs) in patients with type 2 diabetes. Clin. Exp. Med., 2006, 6, 191-193.
292. Ouslimani, N.; Mahrouf, M.; Peynet, J.; Bonnefont-Rousselot, D.; Cosson, C.; Legrand, A.; Beaudeux, J.L. Metformin reduces endothelial cell expression of both the receptor for advanced glycation end products and lectin-like oxidized receptor 1. Metabolism, 2007, 56, 308-313.
293. Meiners, I.; Hauschildt, S.; Nieber, K.; Münch, G. Pentoxyphylline and propentophylline are inhibitors of TNF-alpha release in monocytes activated by advanced glycation endproducts. J. Neural. Transm., 2004, 111, 441-447.
294. Guiotto, A.; Calderan, A.; Ruzza, P.; Borin, G. Carnosine and carnosine-related antioxidants: a review. Curr. Med. Chem., 2005, 12, 2293-2315.
295. Anekonda, T.S. Resveratrol--a boon for treating Alzheimer's disease? Brain Res. Rev., 2006, 52, 316-326.
296. Imai H, Graham DI, Masayasu H, Macrae IMAntioxidant ebselen reduces oxidative damage in focal cerebral ischemia. Free Radic. Biol. Med., 2003, 34, 56-63.
297. Vlad, S.C.; Miller, D.R.; Kowall, N.W.; Felson, D.T. Protective effects of NSAIDs on the development of Alzheimer disease. Neurology, 2008, 70, 1672-1677.
298. Johnson, J.A.; Johnson, D.A.; Kraft, A.D.; Calkins, M.J.; Jakel, R.J.; Vargas, M.R.; Chen, P.C.; The Nrf2-ARE pathway: an indicator and modulator of oxidative stress in neurodegeneration. Ann. NY Acad. Sci., 2008, 1147, 61-69.
299. Lee, J.M.; Calkins, M.J.; Chan, K.; Kan, Y.W.; Johnson, J.A. Identification of the NF-E2-related factor-2-dependent genes conferring protection against oxidative stress in primary cortical astrocytes using oligonucleotide microarray analysis. J. Biol. Chem., 2003, 278, 12029-12038.
300. Shih, A.Y.; Johnson, D.A.; Wong, G.; Kraft, A.D.; Jiang, L.; Erb, H.; Johnson, J.A.; Murphy, T.H. Coordinate regulation of glutathione biosynthesis and release by Nrf2-expressing glia potently protects neurons from oxidative stress. J. Neurosci., 2003, 23, 3394-3406.
301. Kraft AD, Johnson DA, Johnson JANuclear factor E2-related factor 2-dependent antioxidant response element activation by tertbutylhydroquinone and sulforaphane occurring preferentially in astrocytes conditions neurons against oxidative insult. J. Neurosci., 2004, 24, 1101-1112.
302. Calkins MJ, Jakel RJ, Johnson DA, Chan K, Kan YW, Johnson JA.Protection from mitochondrial complex II inhibition in vitro and in vivo by Nrf2-mediated transcription. Proc. Natl. Acad. Sci. USA, 2005, 102, 244-249.
303. Zhao, X.; Sun, G.; Zhang, J.; Strong, R.; Dash, P.K.; Kan, Y.W.; Grotta, J.C.; Aronowski, J. Transcription factor Nrf2 protects the brain from damage produced by intracerebral hemorrhage. Stroke, 2007, 38, 3280-3286.
304. Zhao, J.P.; Constantine-Paton, M. NR2A-/- mice lack long-term potentiation but retain NMDA receptor and L-type Ca2 channel- dependent long-term depression in the juvenile superior colliculus. J. Neurosci., 2007, 27, 13649-13654.
305. Spitsin, S.V.; Scott, G.S.; Mikheeva, T.; Zborek, A.; Kean, R.B.; Brimer, C.M.; Koprowski, H.; Hooper, D.C. Comparison of uric acid and ascorbic acid in protection against EAE. Free Radic. Biol. Med., 2002, 33, 1363-1371.
306. Hooper, D.C.; Scott, G.S.; Zborek, A.; Mikheeva, T.; Kean, R.B.; Koprowski, H.; Spitsin, S.V. Uric acid, a peroxynitrite scavenger, inhibits CNS inflammation, blood-CNS barrier permeability changes, and tissue damage in a mouse model of multiple sclerosis. FASEB J., 2000, 14, 691-698.
307. Yu, Z.F.; Bruce-Keller, A.J.; Goodman, Y.; Mattson, M.P. Uric acid protects neurons against excitotoxic and metabolic insults in cell culture, and against focal ischemic brain injury in vivo. J. Neurosci. Res., 1998, 53, 613-625.
308. Scott, G.S.; Cuzzocrea, S.; Genovese, T.; Koprowski, H.; Hooper, D.C. Uric acid protects against secondary damage after spinal cord injury. Proc. Natl. Acad. Sci. USA, 2005, 102, 3483-3488.
309. Mancuso, M.; Orsucci, D.; Volpi, L.; Calsolaro, V.; Siciliano, G. Coenzyme Q10 in neuromuscular and neurodegenerative disorders. Curr. Drug Targets, 2010, 11, 111-211.
310. [310] Kearney, M.; Orrell, R.W.; Fahey, M.; Pandolfo, M. Antioxidants and other pharmacological treatments for Friedreich ataxia. Cochrane Database Syst. Rev., 2009, 4, CD007791.
311. Wang, X. The antiapoptotic activity of melatonin in neurodegenerative diseases. CNS Neurosci. Ther., 2009, 15, 345-357.
312. Pedersen, M.Ø.; Jensen, R.; Pedersen, D.S.; Skjolding, A.D.; Hempel, C.; Maretty, L.; Penkowa, M. Metallothionein-I+II in neuroprotection. Biofactors, 2009, 35, 315-325.
313. Espejo, C.; Carrasco, J.; Hidalgo, J.; Penkowa, M.; Garcia, A.; Sáez-Torres, I.; Martínez-Cáceres, E.M. Differential expression of metallothioneins in the CNS of mice with experimental autoimmune encephalomyelitis. Neuroscience, 2001, 105, 1055-1065.
314. Penkowa, M.; Espejo, C.; Ortega-Aznar, A.; Hidalgo, J.; Montalban, X.; Martínez Cáceres, M. Metallothionein expression in the central nervous system of multiple sclerosis patients. Cell. Mol. Life Sci., 2003, 60, 1258-1266.
315. Penkowa, M.; Espejo, C.; Martínez-Cáceres, E.M.; Montalban, X.; Hidalgo, J. Increased demyelination and axonal damage in metallothionein I+II-deficient mice during experimental autoimmune encephalomyelitis. Cell. Mol. Life Sci., 2003, 60, 185-197.
316. Penkowa, M.; Espejo, C.; Martínez-Cáceres, E.M.; Poulsen, C.B.; Montalban, X.; Hidalgo, J. Altered inflammatory response and increased neurodegeneration in metallothionein I+II deficient mice during experimental autoimmune encephalomyelitis. J. Neuroimmunol., 2001, 119, 248-260.
317. Whitnall, M.; Richardson, D.R. Iron: a new target for pharmacological intervention in neurodegenerative diseases. Semin. Pediatr. Neurol., 2006, 13, 186-197.
318. Shoham, S.; Youdim, M.B. Iron involvement in neural damage and microgliosis in models of neurodegenerative diseases. Cell Mol. Biol., 2000, 46, 743-760.
319. Zecca, L.; Youdim, M.B.; Riederer, P.; Connor, J.R.; Crichton, R.R. Iron, brain ageing and neurodegenerative disorders. Nat. Rev. Neurosci., 2004, 5, 863-873.
320. Smith, M.A.; Harris, P.L.; Sayre, L.M.; Perry, G. Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc. Natl. Acad. Sci. USA, 1997, 94, 9866-9868.
321. Atwood, C.S.; Huang, X.; Moir, R.D.; Tanzi, R.E.; Bush, A.I. Role of free radicals and metal ions in the pathogenesis of Alzheimer's disease. Met. Ions Biol. Syst., 1999, 36, 309-364.
322. Gorell, J.M.; Ordidge, R.J.; Brown, G.G.; Deniau, J.C.; Buderer, N.M.; Helpern, J.A. Increased iron-related MRI contrast in the substantia nigra in Parkinson's disease. Neurology, 1995, 45, 1138-1143.
323. Wong, A.; Yang, J.; Cavadini, P.; Gellera, C.; Lonnerdal, B.; Taroni, F.; Cortopassi, G. The Friedreich's ataxia mutation confers cellular sensitivity to oxidant stress which is rescued by chelators of iron and calcium and inhibitors of apoptosis. Hum. Mol. Genet., 1999, 8, 425-430.
324. Praticò, D. Evidence of oxidative stress in Alzheimer's disease brain and antioxidant therapy: lights and shadows. Ann. NY Acad. Sci., 2008, 1147, 70-78.
325. Bostanci, M.O.; Bas, O.; Bagirici, F. Alpha-tocopherol decreases iron-induced hippocampal and nigral neuron loss. Cell. Mol. Neurobiol., 2010, 30, 389-394.
326. Cherny, R.A.; Atwood, C.S.; Xilinas, M.E.; Gray, D.N.; Jones, W.D.; McLean, C.A.; Barnham, K.J.; Volitakis, I.; Fraser, F.W.; Kim, Y.; Huang, X.; Goldstein, L.E.; Moir, R.D.; Lim, J.T.; Beyreuther, K.; Zheng, H.; Tanzi, R.E.; Masters, C.L.; Bush, A.I. Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron, 2001, 30, 665-676.
327. Ritchie, C.W.; Bush, A.I.; Mackinnon, A.; Macfarlane, S.; Mastwyk, M.; MacGregor, L.; Kiers, L.; Cherny, R.; Li, Q.X.; Tammer, A.; Carrington, D.; Mavros, C.; Volitakis, I.; Xilinas, M.; Ames, D.; Davis, S.; Beyreuther, K.; Tanzi, R.E.; Masters, C.L. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch. Neurol., 2003, 60, 1685-1691.
328. Kaur, D.; Yantiri, F.; Rajagopalan, S.; Kumar, J.; Mo, J.Q.; Boonplueang, R.; Viswanath, V.; Jacobs, R.; Yang, L.; Beal, M.F.; DiMonte. D.; Volitaskis, I.; Ellerby, L.; Cherny, R.A.; Bush, A.I.; Andersen, J.K. Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease. Neuron, 2003, 37, 899-909.
329. Nguyen, T.; Hamby, A.; Massa, S.M. Clioquinol down-regulates mutant huntingtin expression in vitro and mitigates pathology in a Huntington's disease mouse model. Proc. Natl. Acad. Sci. USA, 2005, 102, 11840-11845.
330. Wolfe, D.; Wechuck, J.; Krisky, D.; Mata, M.; Fink, D.J. A clinical trial of gene therapy for chronic pain. Pain Med., 2009, 10, 1325-1330.
331. Mangas, A.; Coveñas, R.; Bodet, D.; Duleu, S.; Geffard, M. A new drug candidate (GEMSP) for multiple sclerosis. Curr. Med. Chem., 2009, 16, 3203-3214.
332. Bolognesi, M.L.; Cavalli, A.; Melchiorre, C. Memoquin: a multi- target-directed ligand as an innovative therapeutic opportunity for Alzheimer's disease. Neurotherapeutics, 2009, 6, 152-162.
333. Bolton, W.K.; Cattran, D.C.; Williams, M.E.; Adler, S.G.; Appel, G.B.; Cartwright, K.; Foiles, P.G.; Freedman, B.I.; Raskin, P.; Ratner, R.E.; Spinowitz, B.S.; Whittier, F.C.; Wuerth, J.P. ACTION I Investigator Group. Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy. Am. J. Nephrol., 2004, 24, 32-40.
334. Miyata, T.; van Ypersele de Strihou, C.; Ueda, Y.; Ichimori, K.; Inagi, R.; Onogi, H.; Ishikawa, N.; Nangaku, M.; Kurokawa, K. Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: biochemical mechanisms. J. Am. Soc. Nephrol., 2002, 13, 2478-2487.
335. Yamagishi, S.; Ueda, S.; Matsui, T.; Nakamura, K.; Okuda, S. Role of advanced glycation end products (AGEs) and oxidative stress in diabetic retinopathy. Curr. Pharm. Des., 2008, 14, 962-968.
336. Yoshida, T.; Yamagishi, S.; Nakamura, K.; Matsui, T.; Imaizumi, T.; Takeuchi, M.; Koga, H.; Ueno, T.; Sata, M. Telmisartan inhibits AGE-induced C-reactive protein production through downregulation of the receptor for AGE via peroxisome proliferator-activated receptor-gamma activation. Diabetologia, 2006, 12, 3094-3099.
337. Matsui, T.; Yamagishi, S.; Takeuchi, M.; Ueda, S.; Fukami, K.; Okuda, S. Irbesartan inhibits advanced glycation end product (AGE)-induced proximal tubular cell injury in vitro by suppressing receptor for AGEs (RAGE) expression. Pharmacol. Res., 2010, 61, 34-39.
338. Candido, R.; Forbes, J.M.; Thomas, M.C.; Thallas, V.; Dean, R.G.; Burns, W.C.; Tikellis, C.; Ritchie, R.H.; Twigg, S.M.; Cooper, M.E.; Burrell, L.M. A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes. Circ. Res., 2003, 92, 785-792.
339. Wang, L.; Zhang, X.; Liu, L.; Cui, L.; Yang, R.; Li, M.; Du, W. Tanshinone II A down-regulates HMGB1, RAGE, TLR4, NF- kappaB expression, ameliorates BBB permeability and endothelial cell function, and protects rat brains against focal ischemia. Brain Res., 2010, 1321, 143-151